Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Medincell's Future 3-5Y Total Revenue Growth Rate is 78.74.
Medincell (OTCPK:MDCLF) Future 3-5Y Total Revenue Growth Rate Explanation
Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Medincell Future 3-5Y Total Revenue Growth Rate Related Terms
MDCLF vs VRTX, REGN, ALNY: Future 3-5Y Total Revenue Growth Rate Comparison
For the Biotechnology subindustry, Medincell's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Future 3-5Y Total Revenue Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Medincell's Future 3-5Y Total Revenue Growth Rate falls into.
What does a Future 3-5Y Total Revenue Growth Rate of 78.74 mean?
Medincell (MDCLF) has a Future 3-5Y Total Revenue Growth Rate of 78.74 as of Jul. 21, 2026. Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period. View historical data for Medincell and its competitors. According to the industry distribution chart, Medincell ranks #113 out of 336 companies in the Biotechnology industry, placing it in the top 33.6%.
Is Medincell's Future 3-5Y Total Revenue Growth Rate too high?
Medincell's current Future 3-5Y Total Revenue Growth Rate is 78.74. The Biotechnology industry median Future 3-5Y Total Revenue Growth Rate is 39.17. Medincell's value of 78.74 is 101% above this industry median. Based on the distribution chart, Medincell ranks #113 out of 336 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medincell has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Future 3-5Y Total Revenue Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #113 out of 336 companies for Future 3-5Y Total Revenue Growth Rate. This puts Medincell in the upper half of its industry. The industry median Future 3-5Y Total Revenue Growth Rate is 39.17. Medincell's value of 78.74 is 101% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y Total Revenue Growth Rate for a Biotechnology company?
The median Future 3-5Y Total Revenue Growth Rate among Biotechnology companies is 39.17, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y Total Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y Total Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current Future 3-5Y Total Revenue Growth Rate of 78.74 is 101% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y Total Revenue Growth Rate mean?
A high Future 3-5Y Total Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period. View historical data for Medincell and its competitors. For the Biotechnology industry, the median Future 3-5Y Total Revenue Growth Rate is 39.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current Future 3-5Y Total Revenue Growth Rate is 78.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Future 3-5Y Total Revenue Growth Rate of 78.74. The stock's GF Value™ is $30.28, compared to a current price of $34.39 — trading 13.6% above its estimated fair value. The current Future 3-5Y Total Revenue Growth Rate is 78.74 and 101% above the Biotechnology industry median of 39.17. Medincell's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y Total Revenue Growth Rate calculated?
Future 3-5Y Total Revenue Growth Rate is calculated from a company's financial statements. For Medincell (MDCLF), the current Future 3-5Y Total Revenue Growth Rate is 78.74 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 13.6% above its estimated GF Value™ of $30.28.
Key valuation signals for MDCLF:
Future 3-5Y Total Revenue Growth Rate: 78.74
GF Value™: $30.28 vs. price of $34.39 (13.6% above fair value)
Industry Position: 101% above the Biotechnology median (#113 of 336)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
80GF Score
Get the complete analysis for MDCLF
Future 3-5Y Total Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
